Allegro Diagnostics Presents Positive AEGIS I Trial Results of BronchoGen Genomic Test to Improve Diagnosis of Lung Cancer at Annual CHEST Meeting
Published: Oct 23, 2012
MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today presented positive results from the AEGIS I (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial, which demonstrate the diagnostic accuracy of the BronchoGen™ genomic test in combination with bronchoscopy. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the Company’s molecular testing platform that utilizes gene expression of cytologically normal epithelial cells in the respiratory tract to aid in the diagnosis of lung cancer. Duncan Whitney, Ph.D., Senior Vice President, Research, Development and Technical Operations of Allegro Diagnostics and the study’s director, presented the results, “Bronchial Airway Gene-expression Testing Improves the Diagnostic Yield of Bronchoscopy for Lung Cancer: Results of the AEGIS Trial,” during a late-breaking abstract session at the 78th annual meeting of the American College of Chest Physicians (CHEST). CHEST is being held at the Georgia World Congress Center in Atlanta, October 20-25, 2012. The abstract will also appear in a supplement to the October 2012 issue of CHEST.